A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Inclusion Criteria: * Histologically confirmed ALK-positive locally-advanced or metastatic solid tumor excluding lung cancer * ALK-positive tumor as per Foundation Medicine, Inc (FMI) next-generation sequencing (NGS) (NGS F1CDx, F1LCDx, or F1HEME) or per local accredited laboratory using validated NGS testing of tumor tissue or peripheral blood * No alternative effective standard therapy available, or standard therapy considered unsuitable or intolerable to the participant * Other cancer therapies are allowed, including investigational drugs, if any treatment-related toxicities (excluding alopecia) have resolved to grade \</= 1 or to laboratory values as defined by the protocol * Measurable disease at baseline as assessed by the Investigator per RECIST v1.1 or RANO criteria (for participants with primary CNS tumors) * Life expectancy of at least 12 weeks * Eastern cooperative oncology group (ECOG) performance status of 0-2 * Adequate hemataologic, hepatic, and renal function * Participants with primary central nervous system (CNS) tumors are available * Participants with brain or leptomeningeal metastasis are allowed in the study if asymptomatic and if they meet additional criteria as defined by the protocol * Willingness to comply with study procedures * Willingness to comply with home-base approach and visits by Mobile Nurses * Ability to swallow alectinib capsules intact * Women of childbearing potential must test negative for pregnancy at screening and prior to the first…